New data shows improved prophylactic effectiveness with Sobi’s Elocta
Annualised bleed rate among haemophilia A patients was significantly lower in real-world setting
Read More
Tag: Elocta
Successful Elocta bid should widen access to the drug in the UK
Through an agreement with the NHS and Sobi UK, people living with haemophilia A in the UK will have increased access to Elocta following a successful bid in the UK’s Haemophilia A Tender
Read More
Ireland procures Sobi therapies for all haemophilia patients
The Republic of Ireland has become the first country in Europe to switch its entire population with haemophilia A and B treated with short-acting replacement clotting factors to Swedish Orphan Biovitrum’s (Sobi) extended half-life therapies Elocta and Alprolix.
Read More
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
- Johnson & Johnson seeks EMA approval for teclistamab–daratumumab combination
- HUTCHMED begins phase 3 stage of pancreatic cancer trial
- Zenas reports strong phase 3 results for obexelimab in IgG4-related disease
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
